Skip to content

MiMedx Group MDXG Free cash flow margin

Free cash flow margin at other companies

IAR
Integra LifeSciencesIART
3.8%-6.3pp
Artivion logo
ArtivionAORT
-0.1%-2.5pp
Solventum logo
SolventumSOLV
4.6%-13.9pp
Vericel logo
VericelVCEL
16.3%
Enovis logo
EnovisENOV
-3.1%-1.1pp
Tactile Systems Technology logo
Tactile Systems TechnologyTCMD
11.4%-1.5pp

Other financials

Income statement

See full
Revenue$59.0M-33.1%
Gross profit$41.6M-41.9%
Operating income-$16.0M-295%
Net income-$10.9M-255%
EPS (diluted)-$0.07-240%

Balance sheet

See full
Cash & equivalents$159.8M+50.1%
Total debt$17.6M-5.7%
Total equity$242.9M+19.8%
Total assets$308.7M+14.1%

Cash flow

See full
Operating cash flow$1.9M-64.5%
CapEx$570.0K+51.2%
Free cash flow$1.3M-73.4%

Valuation

See full
Market cap$567.48M-33.9%
Enterprise value$425.3M-44.8%
P/E18.5×-2.9×
P/S1.5×-1.0×

Profitability

See full
Gross margin81%-0.9pp
Operating margin10.2%-5.1pp
Net margin7.9%-3.5pp

Returns & leverage

See full
Return on equity13.8%-8.6pp
Debt / equity0.1×0.0×
Current ratio5.4×+0.7×

Where this comes from

Calculated from MiMedx Group’s reported figures.

Based on trailing twelve months.

The official record: MiMedx Group’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about MiMedx Group's free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MiMedx Group's free cash flow margin?
MiMedx Group (MDXG) reported free cash flow margin of 17.8% in Q1 2026.
How has MiMedx Group's free cash flow margin changed year-over-year?
MiMedx Group's free cash flow margin decreased by 2.9% year-over-year, from 18.3% to 17.8%.
What is the long-term trend for MiMedx Group's free cash flow margin?
Over 4 years (2020 to 2025), MiMedx Group's free cash flow margin has grown at a 5.8% compound annual growth rate (CAGR), from -13.9% to 17.4%.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.